{"id":"tumor-necrosis-factor-inhibitors-tnfi","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Anakinra","action":"Avoid","effect":"Increased risk of infections"},{"drug":"Azathioprine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Cyclophosphamide","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Etanercept","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Glatiramer acetate","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Hydroxychloroquine","action":"Monitor","effect":"Increased risk of retinal toxicity"},{"drug":"Immunosuppressants (e.g., azathioprine, cyclophosphamide, cyclosporine)","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Live vaccines","action":"Avoid","effect":"Increased risk of infections"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Mycophenolate mofetil","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Thalidomide","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Vaccines (non-live)","action":"Monitor","effect":"Decreased response to vaccine"}],"commonSideEffects":[{"effect":"Injection site reaction","drugRate":"8.2%","placeboRate":"","totalAtRisk":98,"totalAffected":8,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"4.1%","placeboRate":"","totalAtRisk":98,"totalAffected":4,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"4.1%","placeboRate":"","totalAtRisk":98,"totalAffected":4,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"4.1%","placeboRate":"","totalAtRisk":98,"totalAffected":4,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"3.1%","placeboRate":"","totalAtRisk":98,"totalAffected":3,"trialsReporting":1},{"effect":"Back pain","drugRate":"3.1%","placeboRate":"","totalAtRisk":98,"totalAffected":3,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"2.0%","placeboRate":"","totalAtRisk":98,"totalAffected":2,"trialsReporting":1},{"effect":"rash","drugRate":"1.4%","placeboRate":"","totalAtRisk":148,"totalAffected":2,"trialsReporting":2},{"effect":"autoimmune disorder","drugRate":"1.4%","placeboRate":"","totalAtRisk":148,"totalAffected":2,"trialsReporting":2},{"effect":"otitis media","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"tooth infection","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"urticaria","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"sinusitis","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"INR increased","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"papulopustular rash","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"dehydration","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"Ear pain","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"upper respiratory infection","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"cough","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"thromboembolic event","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"nausea","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"eye infection","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"neck pain","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"diarrhea","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"periodontal disease","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"nasal congestion","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"urinary tract infection","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"fall","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"gum infection","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"colitis","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"pulmonary nodule","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"bone infection","drugRate":"1.4%","placeboRate":"","totalAtRisk":74,"totalAffected":1,"trialsReporting":1},{"effect":"Vulvovaginal candidiasis","drugRate":"0.0%","placeboRate":"","totalAtRisk":23,"totalAffected":0,"trialsReporting":1},{"effect":"Blood triglycerides increased","drugRate":"0.0%","placeboRate":"","totalAtRisk":98,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal burning sensation","drugRate":"0.0%","placeboRate":"","totalAtRisk":23,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal dryness","drugRate":"0.0%","placeboRate":"","totalAtRisk":23,"totalAffected":0,"trialsReporting":1}],"contraindications":["Severe Heart Failure (NYHA class III-IV)","Active Tuberculosis","Active Sepsis or Serious Infections","Demyelinating Diseases","Latent Tuberculosis","Hepatitis B","Recurrent Infections","Mild-to-Moderate Heart Failure (NYHA Class I-II)","HIV Infection","Malignancy History","Live Vaccines","Combination with Other Immunosuppressants"],"specialPopulations":{"Pregnancy":"Women who discontinued their TNFi during pregnancy had a higher risk of peri- or postpartum flare compared to those who continued their TNFi throughout pregnancy. Women who continued their TNFi throughout pregnancy had 3 (3/28, 10.7%) adverse pregnancy outcomes, including one case of preterm birth and two cases of intrauterine growth restriction, and one case of HELLP syndrome. Six (6/32, 18.7%) postpartum flares occurred.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tumor-necrosis-factor-inhibitors-tnfi","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:34:19.297634+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:34:29.537565+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:34:20.771357+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tumor-necrosis-factor-inhibitors-tnfi","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:34:30.103315+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2074849/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:34:31.606538+00:00"}},"allNames":"tumor necrosis factor inhibitors (tnfi)","offLabel":[],"timeline":[],"aiSummary":"Tumor necrosis factor inhibitors (TNFi) from Pfizer Inc. are used to treat various inflammatory conditions. They work by inhibiting the action of tumor necrosis factor, a protein involved in inflammation. Key indications include Rheumatoid Arthritis, Psoriatic Arthritis, and Plaque Psoriasis. TNFi drugs have shown clinical differentiation in reducing symptoms and improving quality of life for patients. Commercially, they have been highly significant, generating $63.6B in revenue. Pipeline developments for TNFi drugs are ongoing, with researchers exploring new indications and formulations.","brandName":"tumor necrosis factor inhibitors (TNFi)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"tumor necrosis factor","novelty":"best-in-class","modality":"monoclonal antibody","drugClass":"biologic","explanation":"","oneSentence":"","technicalDetail":"TNFi drugs specifically target the p55 and p75 TNF receptors, inhibiting the downstream signaling pathways that lead to inflammation. This results in a reduction in pro-inflammatory cytokines and a decrease in inflammation. TNFi drugs have been shown to be effective in reducing symptoms and improving quality of life for patients with various inflammatory conditions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Biologic — patent protected","currentRevenue":"","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=tumor-necrosis-factor-inhibitors-tnfi","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tumor-necrosis-factor-inhibitors-tnfi","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:51.542588+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Abatacept","company":"Bristol-Myers Squibb","advantage":"T-cell co-stimulation blocking agent"},{"name":"Rituximab","company":"Roche","advantage":"Chimeric anti-CD20-depleting monoclonal antibody"},{"name":"Tocilizumab","company":"Roche","advantage":"IL-6 receptor monoclonal antibody"}],"genericName":"tumor-necrosis-factor-inhibitors-tnfi","indications":{"approved":[{"name":"Rheumatoid Arthritis","regulator":"FDA"},{"name":"Psoriatic Arthritis","regulator":"FDA"},{"name":"Ankylosing Spondylitis","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Plaque Psoriasis","regulator":"FDA"},{"name":"Ulcerative Colitis","regulator":"FDA"},{"name":"Crohn's Disease","regulator":"FDA"},{"name":"Axial Spondyloarthritis","regulator":"FDA"},{"name":"Psoriatic Arthritis with Distal Interphalangeal Involvement","regulator":"FDA"},{"name":"Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Moderate to Severe Ulcerative Colitis","regulator":"FDA"},{"name":"Moderate to Severe Crohn's Disease","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Moderate to Severe Plaque Psoriasis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Polyarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Enthesitis","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Systemic Features","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT06905288","phase":"","title":"Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-02","conditions":"Ankylosing Spondylitis","enrollment":70},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT06440629","phase":"PHASE4","title":"Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2024-08-20","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT02714881","phase":"","title":"Lipids, Inflammation, and CV Risk in RA","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-10-17","conditions":"Rheumatoid Arthritis, Cardiovascular Disease","enrollment":74},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT06653634","phase":"PHASE4","title":"Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-10-24","conditions":"Juvenile Idiopathic Arthritis","enrollment":150},{"nctId":"NCT05350644","phase":"","title":"Inflammatory Bowel Disease(IBD), Treatment Response","status":"TERMINATED","sponsor":"University of Southern Denmark","startDate":"2022-02-08","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease","enrollment":2},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT05031767","phase":"NA","title":"Remote Monitoring of Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2021-09-07","conditions":"Axial Spondyloarthritis","enrollment":243},{"nctId":"NCT05447182","phase":"","title":"People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-06","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT05651373","phase":"","title":"The Clinical Features and Pregnancy Outcomes of RA Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-07-30","conditions":"Rheumatoid Arthritis, Pregnancy Related","enrollment":100},{"nctId":"NCT03331393","phase":"","title":"The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-16","conditions":"Rheumatoid Arthritis","enrollment":265},{"nctId":"NCT03419143","phase":"","title":"Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-02","conditions":"Psoriatic Arthritis (PsA)","enrollment":190},{"nctId":"NCT03663829","phase":"","title":"Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-10-04","conditions":"Rheumatoid Arthritis","enrollment":2052},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT04529902","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-08-17","conditions":"Rheumatoid Arthritis","enrollment":63013},{"nctId":"NCT04115423","phase":"","title":"A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-04-01","conditions":"Infection, Rheumatoid Arthritis","enrollment":9508},{"nctId":"NCT02696798","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-04-12","conditions":"Spondyloarthritis","enrollment":316},{"nctId":"NCT01557348","phase":"","title":"An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":1239},{"nctId":"NCT01613027","phase":"","title":"An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":135}],"_emaApprovals":[{"date":"","name":"tumor necrosis factor inhibitors (TNFi)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2074849","moleculeType":"Unknown","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2074849"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2023 Mar 9","pmid":"36894911","title":"Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States.","journal":"BMC gastroenterology"},{"date":"2023","pmid":"36875090","title":"Case report: Unusual development of hepatocellular carcinoma during immunosuppressive treatments against rheumatoid arthritis overlapping Sjögren's syndrome; cirrhotic steatohepatitis with liver inflammation and fibrosis lurks in autoimmune disorders.","journal":"Frontiers in immunology"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":10,"withResults":3},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:51.542588+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}